Form 4 for BOLD Boundless Bio, Inc.
Accepted 2024-04-04 00:00:00 ET · period of report 2024-04-02 · accession 0001415889-24-010278 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-04-04 | 2024-04-02 | BOLD | Kolchinsky Peter | 10% | C - Cnv Deriv | — | +1.87M | 280.2K | New | — |
| DMI | 2024-04-04 | 2024-04-02 | BOLD | Kolchinsky Peter | 10% | P - Purchase | $16.00 | +312.5K | 1.88M | +20% | +$5.00M |
| DMI | 2024-04-04 | 2024-04-02 | BOLD | Kolchinsky Peter | 10% | C - Cnv Deriv | $0.00 | -36.43M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-02 | C | A | 1,587,912 | — | 1,587,912 | I See footnotes | — | — | (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). |
| 2 | Common | Common Stock | 2024-04-02 | P | A | 15,625 | $16.00 | 295,844 | I See footnotes | — | — | (F4) Held directly by the Nexus Fund II. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 3 | Common | Common Stock | 2024-04-02 | C | A | 280,219 | — | 280,219 | I See footnotes | — | — | (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. (F4) Held directly by the Nexus Fund II. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 4 | Common | Common Stock | 2024-04-02 | P | A | 296,875 | $16.00 | 1,884,787 | I See footnotes | — | — | (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). |
| 5 | Derivative | Series C Preferred Stock | 2024-04-02 | C | D | 2,464,286 | $0.00 | 0 | I See footnotes | — · — to — | 126,373 Common Stock | (F4) Held directly by the Nexus Fund II. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
| 6 | Derivative | Series C Preferred Stock | 2024-04-02 | C | D | 13,964,285 | $0.00 | 0 | I See footnotes | — · — to — | 716,118 Common Stock | (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
| 7 | Derivative | Series B Preferred Stock | 2024-04-02 | C | D | 17,000,000 | $0.00 | 0 | I See footnotes | — · — to — | 871,794 Common Stock | (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
| 8 | Derivative | Series B Preferred Stock | 2024-04-02 | C | D | 3,000,000 | $0.00 | 0 | I See footnotes | — · — to — | 153,846 Common Stock | (F4) Held directly by the Nexus Fund II. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F1) On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date. |